Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01560793 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years
A Phase 1 study, sponsored by VaxInnate Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 224
- Enrollment target
NCT01560793 is a Phase 1 study that has completed, run by VaxInnate Corporation. The registered enrollment target is 224 participants.
The verdict
NCT01560793, a Phase 1 study, has completed, sponsored by VaxInnate Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 224 participants
- Enrollment target
Study Summary
This study will evaluate the safety and immunogenicity of VAX161B \[STF2.HA5 H5N1\], a recombinant, inactivated, subunit influenza vaccine given as a two dose regimen at a range of doses.
Interventions
- BIOLOGICAL VAX161 [STF2.HA5 H5N1]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2012-06 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01560793
The ClinicalTrials.gov registry entry for NCT01560793 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VaxInnate Corporation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VAX161 [STF2.HA5 H5N1] is the first listed.
NCT01560793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01560793 about?
NCT01560793 is a clinical study titled "Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years". This study will evaluate the safety and immunogenicity of VAX161B \[STF2.HA5 H5N1\], a recombinant, inactivated, subunit influenza vaccine given as a two dose regimen at a range of doses.
What is the current status of trial NCT01560793?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 224 participants. The study started on 2012-06. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01560793?
The interventions under investigation include: VAX161 [STF2.HA5 H5N1] (BIOLOGICAL).
Who is sponsoring clinical trial NCT01560793?
This trial is sponsored by VaxInnate Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.